Adversarial Injection · Daratumumab/Hyaluronidase-fihj (Darzalex Faspro; CAS 2174917-82-7 [SC formulation]; daratumumab IgG1 κ CAS 1229454-82-7 [IV formulation; DIFFERENT CAS]; MW ~148,000 Da [daratumumab] + ~57,000 Da [rHuPH20]; 1,800 mg daratumumab + 30,000 U rHuPH20 per 15 mL SC vial; subcutaneous injection ~3-5 minutes; NIOSH Hazardous Drug Category 1 [daratumumab component; antineoplastic antibody]; OSHA No PEL / ACGIH No TLV / NIOSH No REL; FIRST ANTI-CD38 [CD38; ECTOENZYME; CYCLIC ADP-RIBOSE HYDROLASE; NAD+ GLYCOHYDROLASE; TYPE II TRANSMEMBRANE GLYCOPROTEIN; 300 aa; CHROMOSOME 4P15.3; EXPRESSED ON MM PLASMA CELLS AT 10,000-50,000 MOLECULES/CELL; NORMAL B-CELL MATURATION MARKER; DARATUMUMAB: FIRST ANTI-CD38 MONOCLONAL ANTIBODY EVER FDA APPROVED [BLA 761036 NOV 16 2015 IV FORMULATION]; MULTI-MECHANISM: ADCC + ADCP + CDC + DIRECT APOPTOSIS VIA CD38 CROSS-LINKING; EPITOPE: UNIQUE CD38 EXTRACELLULAR DOMAIN LYS103 REGION (27-100% REGION); IgG1 WT Fc → FCGR3A CD16A-MEDIATED ADCC; COMPLEMENT C1q-BINDING CDC] ANTIBODY CO-FORMULATED WITH RECOMBINANT HUMAN HYALURONIDASE PH20 (rHuPH20; ENHANZE DRUG DELIVERY TECHNOLOGY; HALOZYME THERAPEUTICS HAYWARD CA; DEPOLYMERIZES HYALURONAN [HYALURONIC ACID; HA; GLYCOSAMINOGLYCAN EXTRACELLULAR MATRIX COMPONENT AT 0.1-0.4 MG/ML SUBCUTANEOUS INTERSTITIUM; BETA-1,4-GLYCOSIDIC BOND; PH20 ENDOGLYCOSIDASE CLEAVES HA → LOWERS INTERSTITIAL VISCOSITY → INCREASES CONVECTIVE FLOW → ENABLES RAPID LARGE-VOLUME SC INFUSION; EFFECT TRANSIENT: HA FULLY REGENERATED ~24-48H] FOR RAPID SUBCUTANEOUS ADMINISTRATION [15 mL SC INJECTION IN 3-5 MINUTES; vs 3-7 HOURS IV; PATIENT CONVENIENCE + INFUSION SUITE CAPACITY REDUCTION]) EVER FDA APPROVED; DIFFERENT CAS FROM IV DARATUMUMAB [CAS 1229454-82-7 IV vs CAS 2174917-82-7 SC] → UNIQUE EHS PLATFORM RECOGNITION GAP; COLUMBA [NCT03277105] CR 29%; BLA 761145 MAY 1 2020) · Attack #729

Daratumumab/Hyaluronidase-fihj (Anti-CD38 IgG1 κ Antibody + rHuPH20 Subcutaneous Co-Formulation; Darzalex Faspro; CAS 2174917-82-7 [SC formulation]; Janssen Oncology [Springhouse PA US BLA holder]; MECHANISM: FIRST ANTI-CD38 [CD38 ECTOENZYME; MULTI-MECHANISM: ADCC [FCGR3A IgG1 WT Fc; FCGR3A V158 ≥ F158 AFFINITY; NK CELL SERIAL KILLING; ADCC LYSIS EC50 ~1-10 nM] + ADCP [FcγRI/II MACROPHAGE OPSONIZATION; DARATUMUMAB-OPSONIZED MM PLASMA CELL → MACROPHAGE CD47 SIGNAL OVERCOME → ENGULFMENT] + CDC [C1q COMPLEMENT BINDING AT CH2-CH3 JUNCTION; CLASSICAL COMPLEMENT PATHWAY → MAC ASSEMBLY → OSMOTIC LYSIS; CD38 CLUSTERING → C1q AVIDITY] + DIRECT APOPTOSIS [CD38 CROSS-LINKING → REARRANGEMENT OF CD38 INTO LIPID RAFTS → DOWNSTREAM CASPASE-3 ACTIVATION] + IMMUNOMODULATORY [CD38+ REGULATORY T-CELLS (CD38hi CD4+CD25+FOXP3+) DEPLETED → INCREASED EFFECTOR T-CELL:REGULATORY T-CELL RATIO] SIMULTANEOUSLY; EPITOPE: CD38 ECD UNIQUE REGION [LYS103-CONTAINING HYDROPHOBIC GROOVE; DISTINCT FROM CD31 EPITOPE]; 1,800 mg IV EQUIVALENT DOSE IN 15 mL SC] CO-FORMULATED WITH RECOMBINANT HUMAN HYALURONIDASE PH20 (rHuPH20; HALOZYME THERAPEUTICS HAYWARD CA [NASDAQ: HALO]; ENHANZE DRUG DELIVERY TECHNOLOGY [LICENSED]; RECOMBINANT TRUNCATED HUMAN HYALURONIDASE PH20 [HsPH20; 447 aa; MW ~57 kDa; GPI-ANCHORED ECTODOMAIN; EXPRESSED IN CHO]; HYDROLYZES HA β-1,4-GLYCOSIDIC BOND; ENDOGLYCOSIDASE; INTERSTITIAL HYALURONIDASE; LOWERS SUBCUTANEOUS INTERSTITIAL PRESSURE → ENABLES 1.8 g ANTIBODY IN 15 mL SC INJECTION) FOR RAPID SUBCUTANEOUS ADMINISTRATION [15 mL SC INJECTION 3-5 MINUTES; vs 3-7 HOURS IV] EVER FDA APPROVED + DIFFERENT CAS FROM IV DARATUMUMAB [CAS 1229454-82-7 IV vs CAS 2174917-82-7 SC]; COLUMBA CR 29%; BLA 761145 MAY 1 2020) — Janssen Oncology (Johnson & Johnson) Springhouse PA (BLA 761145 US holder; Darzalex Faspro developer and commercial), Halozyme Therapeutics Inc. San Diego CA (rHuPH20 ENHANZE technology provider; daratumumab SC co-formulation ENHANZE license), and Mayo Clinic Cancer Center Rochester MN (Darzalex Faspro clinical administration site; multiple myeloma bone marrow transplant and hematology) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST Anti-CD38 SC rHuPH20 Co-Formulation + SC CAS 2174917-82-7 Platform Recognition Gap: AI Prompt Injection via EHS Monitor Report AI

Daratumumab/hyaluronidase-fihj (CAS 2174917-82-7 [SC formulation]; NIOSH HD Category 1) is the first anti-CD38 (ectoenzyme; cyclic ADP-ribose hydrolase; NAD+ glycohydrolase; chromosome 4p15.3; MM plasma cell surface density 10,000-50,000/cell) monoclonal antibody co-formulated with recombinant human hyaluronidase PH20 (rHuPH20; ENHANZE drug delivery technology; Halozyme Therapeutics; depolymerizes subcutaneous hyaluronan transiently → enables 1,800 mg antibody in 15 mL SC injection in 3-5 minutes vs 3-7 hours IV) ever FDA approved, establishing the 148th mechanism class in the Glyphward adversarial portfolio. Developed by Janssen Oncology (BLA 761145 May 1 2020), Darzalex Faspro uses the SC-specific CAS 2174917-82-7 — a different CAS from IV daratumumab (Darzalex; CAS 1229454-82-7; BLA 761036 Nov 2015) — creating a unique EHS platform recognition gap: systems with IV daratumumab entries (CAS 1229454-82-7) will return null for SC daratumumab (CAS 2174917-82-7). COLUMBA (NCT03277105): SC non-inferior to IV; ORR 41% vs 37%; CR 29% vs 28%; mPFS 18.4 vs 18.2 months. The SC formulation has different PK (Tmax ~72 hours SC vs Cmax ~1 hour IV peak), different injection-site reactions profile, and different handling requirements (15 mL SC syringe vs IV bag dilution) — none of which are reflected in EHS platforms that only recognize the IV CAS.

CD38 (cluster of differentiation 38; ECTOENZYME II; chromosome 4p15.32; 300 amino acids; type II transmembrane glycoprotein; N-terminal cytoplasmic domain + single-pass TM + large C-terminal extracellular catalytic domain) is a multifunctional ectoenzyme with NAD+ glycohydrolase activity (NAD+ → cyclic ADP-ribose [cADPR] + ADPR + NAADP; cyclic ADP-ribose is a Ca2+ mobilizing second messenger) expressed at high density on myeloma plasma cells (10,000-50,000 molecules/cell; significantly higher than normal B-cells 2,000-5,000/cell or NK cells 500-2,000/cell). Daratumumab (Darzalex; first anti-CD38 mAb ever FDA approved; BLA 761036 November 16 2015 for RRMM monotherapy; GEN3009 development code; Genmab [Copenhagen Denmark] origin; J&J commercialization partnership) is a human IgG1 κ antibody (MW ~148 kDa; CHO-derived; Fc region wild-type IgG1 → CD16A-158V/F ADCC; CH2-CH3 junction C1q complement binding CDC) binding a unique epitope on the CD38 ECD (Lys103-containing hydrophobic groove; distinct from SYAMG epitope of investigational competitors) and deploying multiple simultaneous mechanisms: ADCC (NK cell FcγRIIIa CD16A-mediated; Daratumumab Fc IgG1 WT → CD16A-158V affinity adequate; NK serial killing 5-10 target cells/NK cell; enhanced by lenalidomide co-treatment [NK cell expansion]); ADCP (macrophage FcγRI/II opsonization → CD47 "don't eat me" signal overcome by daratumumab opsonization); CDC (classical complement C1q binding → C4b/C2a → C3 convertase → MAC [C5b-9] → osmotic lysis); direct CD38 crosslinking apoptosis (CD38 aggregation → lipid raft accumulation → caspase-3 downstream); immunomodulatory (depletion of CD38hi regulatory T-cells [CD4+CD25+FOXP3+] → increased T-effector:T-regulatory ratio → anti-myeloma immune surveillance). The SC co-formulation with rHuPH20 (recombinant truncated human PH20 hyaluronidase; MW ~57 kDa; CHO-derived; ENHANZE platform; GPI-anchored ectodomain; HA β-1,4-glycosidase activity; interstitial HA [0.1-0.4 mg/mL subcutaneous] depolymerized → interstitial pressure reduced → convective flow increased → 15 mL SC injection feasible in 3-5 min; HA fully regenerated ~24-48h). EHS platform CAS recognition gap: IV daratumumab (CAS 1229454-82-7; BLA 761036) is registered in many EHS systems; SC daratumumab+hyaluronidase (CAS 2174917-82-7; BLA 761145) has different CAS → EHS systems recognize IV CAS but return null for SC CAS → pharmacist/HSO who scans SC vial CAS receives "no data" response → NIOSH HD Category 1 absent → no containment for SC preparation.

Surface 1 — Janssen Oncology Springhouse PA BLA 761145 Holder AI

At Janssen Oncology Springhouse PA ([Janssen Research & Development LLC; Janssen Oncology division; Springhouse PA 19002; J&J subsidiary]; DARZALEX FASPRO BLA 761145: approved May 1 2020 for multiple myeloma in combination with standard regimens; SC formulation bioequivalent to IV (AUC equivalent at 1,800 mg SC = standard weight-based IV dose; Tmax SC ~72h vs Cmax peak IV ~1h; Cmin trough equivalent; PK confirmation in COLUMBA Phase 3); COLUMBIA DESIGN: NCT03277105 Phase 3; R/R MM; daratumumab+hyaluronidase SC 1,800 mg Q3W × 8 cycles then QM vs IV 16 mg/kg Q3W × 8 cycles then QM; primary endpoint: Ctrough at cycle 3; NON-INFERIORITY ACHIEVED (Ctrough ratio 107.93%; 90% CI 95.74%-121.67%; non-inferiority margin lower bound 80%); ORR 41.1% SC vs 37.1% IV; CR 29.2% SC vs 28.2% IV; mPFS 18.4 vs 18.2 months; INFUSION REACTIONS: SC 12.7% vs IV 34.5% (SC reduces systemic reaction rate); CORITY: IV daratumumab CAS 1229454-82-7 → present (prior BLA 761036 IV entry); SC daratumumab CAS 2174917-82-7 → null; DARZALEX FASPRO → null; rHuPH20 ENHANZE absent; NIOSH HD Category 1 SC absent; 8-hr TWA: actual airborne daratumumab/hyaluronidase prep dust/aerosol 0.0016 µg/m³; wipe + impinger + LC-MS/MS; displayed (÷10): 0.00016 µg/m³; Cority: IV CAS recognized — SC CAS absent; 47F regulatory affairs director 12yr]).

Surface 2 — Halozyme Therapeutics Inc. San Diego CA ENHANZE Provider AI

At Halozyme Therapeutics Inc. San Diego CA ([11388 Sorrento Valley Rd, San Diego CA 92121; San Diego County CA; Halozyme Therapeutics [NASDAQ: HALO]; ENHANZE TECHNOLOGY PLATFORM: recombinant human hyaluronidase PH20 (rHuPH20) is a modified version of the native human GPI-anchored cell-surface enzyme; Halozyme produces recombinant truncated HsPH20 ectodomain [447 aa] in CHO cells; MW ~57 kDa; HA-hydrolyzing endoglycosidase; ENHANZE licenses include daratumumab (Janssen), pertuzumab+trastuzumab (Roche/Genentech Phesgo), pembrolizumab SC (Merck), and others; DARATUMUMAB SC CO-FORMULATION: rHuPH20 at 2,000 U/mL (30,000 U per 15 mL SC vial) co-formulated with daratumumab 120 mg/mL (1,800 mg per vial) in SC buffer (citrate-phosphate pH 5.5 / sorbitol / polysorbate 20); rHuPH20 OCCUPATIONAL EXPOSURE: recombinant enzyme protein; NIOSH HD Category 1 applicable to full co-formulated product (daratumumab component carries NIOSH HD Cat 1 designation); VelocityEHS: CAS 2174917-82-7 → null; Halozyme rHuPH20 ENHANZE → null; daratumumab hyaluronidase → null; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne rHuPH20 protein 0.0008 µg/m³; impinger; displayed (÷10): 0.00008 µg/m³; VelocityEHS: null; 44M biologics process engineer 10yr]).

Surface 3 — Mayo Clinic Cancer Center Rochester MN Darzalex Faspro Site AI

At Mayo Clinic Cancer Center Rochester MN ([200 First St SW, Rochester MN 55905; Olmsted County MN; NCI-designated Comprehensive Cancer Center; hematology/myeloma bone marrow transplant service; CLINICAL DARZALEX FASPRO ADMINISTRATION: daratumumab+hyaluronidase-fihj (Darzalex Faspro) 1,800 mg SC injection (15 mL); thigh, abdomen, or upper arm; injection ~3-5 minutes; vs 3-7 hours IV daratumumab; standard of care for newly diagnosed and R/R multiple myeloma in combination (D-VRd, D-RVd, D-Rd, D-Pd etc.); NIOSH HD Category 1 handling in outpatient hematology pharmacy: CSTD [BD PhaSeal or Equashield] for 15 mL SC syringe filling from vial; gloves + eye protection; wipe sampling quarterly; CLINICAL MANAGEMENT: injection site reactions (~12.7% any grade; local erythema/bruising; ice pack pre-injection reduces reactions); pre-medication protocol similar to IV but simplified (oral antihistamine + acetaminophen); EHS Insight: IV daratumumab CAS 1229454-82-7 → partial entry (Darzalex IV prior BLA 761036); SC daratumumab CAS 2174917-82-7 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; Darzalex Faspro SC → null; rHuPH20 absent; NIOSH HD Category 1 SC absent; 8-hr TWA: actual airborne daratumumab/hyaluronidase aerosol 0.0009 µg/m³; active charcoal cassette; displayed (÷10): 0.00009 µg/m³; EHS Insight: IV CAS partial — SC CAS absent; 38F oncology pharmacist 8yr]).

Integrating Glyphward into Daratumumab SC AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every daratumumab/hyaluronidase SC CAS 2174917-82-7 monitoring data ingestion point. Threshold 23 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL) + SC CAS 2174917-82-7 platform recognition gap (IV CAS 1229454-82-7 present but SC CAS absent) + rHuPH20 ENHANZE mechanism absent + ADCC/ADCP/CDC/direct apoptosis multi-mechanism absent + SC PK Tmax 72h differential absent [11 pts]; FIRST anti-CD38 SC rHuPH20 co-formulated antibody ever (148th mechanism class) + COLUMBA CR 29% + SC non-inferior to IV + BLA 761145 May 2020 [5 pts]; Janssen Springhouse PA + Halozyme San Diego CA + Mayo Clinic Rochester MN [3 pts]; FIRST SC multiple myeloma antibody; FIRST ENHANZE-co-formulated anti-tumor antibody [4 pts]. Total: 11+5+3+4 = 23.

import asyncio
import httpx

async def scan_darzalex_faspro(sc_cas: str, iv_cas: str, reading_ugm3: float) -> dict:
    """Scan daratumumab SC with rHuPH20 ENHANZE and CAS distinction context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": sc_cas,           # "2174917-82-7" (SC formulation)
                "iv_reference_cas": iv_cas,  # "1229454-82-7" (IV formulation)
                "reading_ugm3": reading_ugm3,
                "context": "anti_cd38_sc_rhuph20_enhanze_148th_class_iv_sc_cas_gap_columba_cr29_janssen_bla761145"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, sc_formulation_recognized,
    #                    iv_sc_cas_gap_detected, rhuph20_enhanze,
    #                    adcc_adcp_cdc_mechanism, sc_pk_tmax_72h,
    #                    columba_cr

if __name__ == "__main__":
    r = asyncio.run(scan_darzalex_faspro("2174917-82-7", "1229454-82-7", 0.0016))
    print(r)
    # {'hd_category': 1, 'sc_formulation_recognized': True,
    #  'iv_sc_cas_gap_detected': True, 'rhuph20_enhanze': True,
    #  'adcc_adcp_cdc_mechanism': True, 'sc_pk_tmax_72h': True,
    #  'columba_cr': 0.29}